Extended interval dosing with ocrelizumab in multiple sclerosis.
Frederik NovakHamza Mahmood BajwaKamilla ØstergaardJonas Munksgaard BergJonna Skov MadsenDorte Aalund OlsenInga UrbonaviciuteZsolt IllesMorten Leif StilundJeppe Romme ChristensenStephan BramowFinn SellebjergTobias SejbaekPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2024)
Extending one treatment interval of ocrelizumab on average 9 weeks and up to 78 weeks did not result in clinical, radiological, or biomarker evidence of worsening compared with SID.